Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AZ3C
|
|||
| Former ID |
DAP000179
|
|||
| Drug Name |
Imatinib
|
|||
| Synonyms |
Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Approved | [1], [2] | |
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.1; ICD-9: 205.1] | Approved | [3], [4] | ||
| Intestinal cancer [ICD-11: 2C0Z] | Phase 3 | [3], [4] | ||
| Lung cancer [ICD-11: 2C25.0] | Phase 2 | [3], [4] | ||
| Systemic mastocytosis [ICD-11: 2A21.0; ICD-9: 202.6, 757.33] | Investigative | [5] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H31N7O
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
|
|||
| InChI |
1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
|
|||
| InChIKey |
KTUFNOKKBVMGRW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 152459-95-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
584799, 822644, 828861, 832827, 841977, 5619104, 7890613, 7979593, 8153249, 14859628, 22394533, 24424247, 26697112, 26737110, 29215405, 29215406, 29224346, 46392211, 46393540, 46505055, 46507948, 46513933, 49655235, 50066026, 50070642, 50100104, 50109856, 50353059, 53788935, 53799240, 56311252, 56311284, 56311359, 56311779, 56311988, 56312022, 56312838, 56313109, 56313183, 56313522, 56313562, 56314521, 57288246, 57288452, 57288559, 57288780, 57322698, 57551951, 57578266, 85171056
|
|||
| ChEBI ID |
CHEBI:45783
|
|||
| ADReCS Drug ID | BADD_D01136 ; BADD_D01137 | |||
| SuperDrug ATC ID |
L01XE01
|
|||
| SuperDrug CAS ID |
cas=152459955
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides eggerthii
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Imatinib can be metabolized by Bacteroides eggerthii. | |||
|
Studied Microbe: Bacteroides stercoris
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Imatinib can be metabolized by Bacteroides stercoris. | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Imatinib can be metabolized by Bacteroides vulgatus. | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Imatinib can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.453; p = 0.028). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Anaerostipes sp.
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Imatinib can be metabolized by Anaerostipes sp. (log2FC = -0.405; p = 0.037). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006806) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687). | |||
| REF 4 | Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. | |||
| REF 5 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | |||
| REF 6 | Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci. 2020 Mar;13(2):238-259. | |||
| REF 7 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 8 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.